Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.61 |
| ▸ | CPT2 | P23786 | 2/20 | 0.57 |
| ▸ | CPT1A | P50416 | 2/20 | 0.57 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208087 | 1.00 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL17629809 | 1.00 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL8767045 | 0.92 | MEN1 (0.62) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL26797580 | 0.92 | MEN1 (0.62) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL26797583 | 0.92 | MEN1 (0.62) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Cadaverine Tartrate SCHEMBL7526527 | 0.89 | MEN1 (0.59) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL1830071 | 0.87 | MEN1 (0.57) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL28171779 | 0.87 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL7031982 | 0.87 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL2994007 | 0.85 | MEN1 (0.65) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149540-A1 | Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury | UNIVERSITY OF ROCHESTER | 2009-06-11 | — | — | US | disclosed |
| EP-1965650-A2 | COMPOSITIONS AND METHODS FOR ATTENUATING MITOCHONDRIA-MEDIATED CELL INJURY | University of Rochester (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007076322-A2 | COMPOSITIONS AND METHODS FOR ATTENUATING MITOCHONDRIA-MEDIATED CELL INJURY | UNIVERSITY OF ROCHESTER (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060122267-A1 | Compositions and methods for attenuating mitochondria-mediated cell injury | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149540-A1 | Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury | SHMT2, TXN2, TXNRD2 | MEN1 4835/4885KMT2A 4350/4885CYP1A2 1061/4885 |
| US-20060122267-A1 | Compositions and methods for attenuating mitochondria-mediated cell injury | SHMT2, TXN2, TXNRD2 | MEN1 4851/4885KMT2A 4391/4885CYP1A2 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.